Cargando…

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy

Radioactive iodine (RAI) treatment of differentiated thyroid cancer has been used in clinical practice for almost 60 years and is generally accepted to be a safe and efficacious treatment. Severe toxicity in the form of radiation pneumonitis, sometimes progressing to fibrosis, and bone marrow suppre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Probst, Stephan, Abikhzer, Gad, Chaussé, Guillaume, Tamilia, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996605/ https://www.ncbi.nlm.nih.gov/pubmed/29889031 http://dx.doi.org/10.4274/mirt.59454

Ejemplares similares

(18)F-fluorodeoxyglucose positron emission tomography/computed tomography in extensive bland portal vein thrombosis from retroperitoneal adenocarcinoma
por: Chaussé, Guillaume, et al.
Publicado: (2019)

Incidental Hydroxyapatite Ocular Implant Uptake on Bone Scan Done for Prostate Cancer Staging: Case Report and Brief Review
por: Chaussé, Guillaume, et al.
Publicado: (2019)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
por: Shinto, Ajit S., et al.
Publicado: (2013)

Efficacy of Dosimetric Versus Empiric Prescribed Activity of (131)I for Therapy of Differentiated Thyroid Cancer
por: Klubo-Gwiezdzinska, Joanna, et al.
Publicado: (2011)

Dosimetry during adjuvant (131)I therapy in patients with differentiated thyroid cancer-clinical implications
por: Szumowski, Piotr, et al.
Publicado: (2021)

Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
por: Rafi, Mohammad, et al.
Publicado: (2018)

I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
por: Lin, Rong, et al.
Publicado: (2015)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

SUN-510 Prolonged RAIA Induced Thyroiditis After 131 I Therapy for Graves’ Hyperthyroidism
por: Aljaberi, Asma Khaled, et al.
Publicado: (2020)

Low-Iodine Diet of 4 Days Is Sufficient Preparation for (131)I Therapy in Differentiated Thyroid Cancer Patients
por: Dekker, Bernadette L, et al.
Publicado: (2021)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration
por: Gomes-Lima, Cristiane J, et al.
Publicado: (2022)

I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
por: Gill, Sana Munir, et al.
Publicado: (2023)

Usefulness of second (131)I treatment in biochemical persistent differentiated thyroid cancer patients
por: Gambale, Carla, et al.
Publicado: (2023)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on (131)I-SPECT/CT
por: Wang, Feng, et al.
Publicado: (2021)

A practical method of I-131 thyroid cancer therapy dose optimization using estimated effective renal clearance
por: Howard, Brandon A, et al.
Publicado: (2017)

30 mCi exploratory scan for two-step dosimetric (131)I therapy in differentiated thyroid cancer patients: A novel approach and case report
por: Wu, Di, et al.
Publicado: (2020)

Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer
por: Okamoto, Shozo, et al.
Publicado: (2013)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
por: Iwano, Shingo, et al.
Publicado: (2020)

Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience
por: Lubin, David J., et al.
Publicado: (2021)

A semiquantitative study of the optimal whole-body imaging time after (131)I therapy for differentiated thyroid cancer
por: Liu, Shuang, et al.
Publicado: (2022)

TPGS-Modified Long-Circulating Liposomes Loading Ziyuglycoside I for Enhanced Therapy of Myelosuppression
por: Song, Tingting, et al.
Publicado: (2021)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Erdheim-Chester Disease: The Importance of Information Integration
por: Nikonova, Anna, et al.
Publicado: (2017)

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis
por: Lin, Shang, et al.
Publicado: (2021)

Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma
por: Zheng, Lei, et al.
Publicado: (2022)

Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment
por: Hussein, Osama, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ckannjtjkt1ri7s8fjc0b8qikf